Jenburkt Pharmaceuticals Ltd. Quarterly Results: Standalone & Consolidated Reports

Quarterly Results

Results Snapshot

YoYQoQ

Figures in Cr

Standalone Quarterly Results

Sep'25

Jun'25

Mar'25

Dec'24

Sep'24

Jun'24

Mar'24

Quarterly Analysis Highlights - QoQ

Net Sales

QoQ Growth in quarter ended Sep 2025 is 28.23% vs -13.45% in Jun 2025

Standalone Net Profit

QoQ Growth in quarter ended Sep 2025 is 30.42% vs -8.78% in Jun 2025

Operating Profit (PBDIT) excl Other Income

QoQ Growth in quarter ended Sep 2025 is 46.21% vs -17.50% in Jun 2025

Interest

QoQ Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Jun 2025

Operating Profit Margin (Excl OI)

QoQ Growth in quarter ended Sep 2025 has improved from Jun 2025

Compare Quarterly Results Of Jenburkt Pharma With

Select Peers

Figures in Cr

Standalone Quarterly Results

Change(INR)

Change(%)

Net Sales

45.56

42.23

3.33

7.89%

Other Operating Income

0.00

Total Operating income

45.56

42.23

3.33

7.89%

Raw Material Cost

2.19

21.26

-19.07

-89.70%

Purchase of Finished goods

6.28

0.00

6.28

(Increase) / Decrease In Stocks

-0.12

1.18

-1.30

-110.17%

Employee Cost

13.93

5.71

8.22

143.96%

Power Cost

0.00

Manufacturing Expenses

0.01

0.00

0.01

Selling and Distribution Expenses

0.00

Other Expenses

10.17

9.06

1.11

12.25%

Total Expenditure (Excl Depreciation)

32.46

37.21

-4.75

-12.77%

Operating Profit (PBDIT) excl Other Income

13.10

5.02

8.08

160.96%

Other Income

2.08

0.37

1.71

462.16%

Operating Profit (PBDIT)

15.18

5.39

9.79

181.63%

Interest

0.11

0.81

-0.70

-86.42%

Exceptional Items

0.00

Gross Profit (PBDT)

15.07

4.58

10.49

229.04%

Depreciation

0.74

1.81

-1.07

-59.12%

Profit Before Tax

14.33

2.77

11.56

417.33%

Tax

4.17

0.56

3.61

644.64%

Provisions and contingencies

0.00

Profit After Tax

10.16

2.21

7.95

359.73%

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

10.16

2.21

7.95

359.73%

Equity Capital

4.41

13.56

-9.15

-67.48%

Face Value

10.00

0.00

Reserves

0.00

Earnings per share (EPS)

23.04

1.63

21.41

1,313.50%

Diluted Earnings per share

23.03

1.63

21.40

1,312.88%

Operating Profit Margin (Excl OI)

28.75%

11.89%

0.00

16.86%

Gross Profit Margin

33.08%

10.85%

0.00

22.23%

PAT Margin

22.30%

5.23%

0.00

17.07%

Public Share Holdings (%)

0.00%

0.00

0.00%

Pledged Promotor Holding (%)

0.00%

0.00

0.00%

Quarterly - Net Sales

Net Sales 45.56 Cr

in Sep 2025

Figures in Cr

QoQ Growth in quarter ended Sep 2025 is 28.23% vs -13.45% in Jun 2025

YoY Growth in quarter ended Sep 2025 is 10.53% vs 7.65% in Sep 2024

Quarterly - Standalone Net Profit

Standalone Net Profit 10.16 Cr

in Sep 2025

Figures in Cr

QoQ Growth in quarter ended Sep 2025 is 30.42% vs -8.78% in Jun 2025

YoY Growth in quarter ended Sep 2025 is 5.83% vs 31.15% in Sep 2024

Quarterly - Operating Profit (PBDIT)

Operating Profit (PBDIT) 13.10 Cr

in Sep 2025

Figures in Cr

QoQ Growth in quarter ended Sep 2025 is 46.21% vs -17.50% in Jun 2025

YoY Growth in quarter ended Sep 2025 is 14.61% vs 25.60% in Sep 2024

Quarterly - Interest

Interest 0.11 Cr

in Sep 2025

Figures in Cr

QoQ Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Jun 2025

YoY Growth in quarter ended Sep 2025 is -8.33% vs 71.43% in Sep 2024

Quarterly - Operating Profit Margin (Excl OI)

Operating Profit Margin (Excl OI) 28.75%

in Sep 2025

Figures in %

QoQ Growth in quarter ended Sep 2025 has improved from Jun 2025

YoY Growth in quarter ended Sep 2025 has improved from Sep 2024